{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:27:12Z","timestamp":1793914032300,"version":"4.8.0"},"reference-count":204,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omton.2026.201171","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:31:51Z","timestamp":1772559111000},"page":"201171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"34","author":[{"given":"Alexandra","family":"Dreyzin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Gava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Lamplugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-2927","authenticated-orcid":false,"given":"Julie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-9410","authenticated-orcid":false,"given":"Sara K.","family":"Silbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201171_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pcl.2014.09.004","article-title":"Biology of childhood acute lymphoblastic leukemia","volume":"62","author":"Bhojwani","year":"2015","journal-title":"Pediatr. Clin. North Am."},{"key":"10.1016\/j.omton.2026.201171_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1053\/j.seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.omton.2026.201171_bib3","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1200\/JCO.2003.08.047","article-title":"CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials","volume":"21","author":"Clarke","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib5","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"M\u00f6ricke","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib6","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib7","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib8","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib9","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib10","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib11","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omton.2026.201171_bib13","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201171_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201171_bib15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201171_bib16","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib19","volume":"2025","author":"Whitehead","year":"2022"},{"key":"10.1016\/j.omton.2026.201171_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib21","unstructured":"Kymriah Product Insert and Medication Guide. (ed. Corporation, N.P.) (U.S. Food and Drug Administration U.S. Food and Drug Administration website)."},{"key":"10.1016\/j.omton.2026.201171_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.healthpol.2024.105153","article-title":"Availability and financing of CAR-T cell therapies: A cross-country comparative analysis","volume":"149","author":"Litvinova","year":"2024","journal-title":"Health Policy"},{"key":"10.1016\/j.omton.2026.201171_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah(R) (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.omton.2026.201171_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201171_bib25","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib27","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib28","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201171_bib29","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib30","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib32","series-title":"Package Insert and M. Guid - KYMRIAH","year":"2025"},{"key":"10.1016\/j.omton.2026.201171_bib33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41392-021-00764-4","article-title":"Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib35","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","article-title":"Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy","volume":"9","author":"Lust","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib36","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1182\/bloodadvances.2025015881","article-title":"Real-world data for tisagenlecleucel in patients with R\/R B-ALL: subgroup analyses from the CIBMTR registry","volume":"9","author":"John","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib37","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib38","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.jtct.2025.02.016","article-title":"Tisagenlecleucel in Practice: Real-World Lessons in Pediatric and Young Adult B-ALL","volume":"31","author":"McNerney","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201171_bib40","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T Cell-Associated Neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib42","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib43","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib44","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib45","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib46","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib47","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.hoc.2025.02.005","article-title":"Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)","volume":"39","author":"Lee","year":"2025","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.omton.2026.201171_bib50","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib51","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/bloodadvances.2025017753","article-title":"10-year experience of CD22 CAR T-cells for children and young adults with B-cell acute lymphoblastic leukemia","volume":"10","author":"Dreyzin","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib52","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2025-4501","article-title":"Overlap of post-CAR T HLH toxicity definitions and their prognostic significance in children and young adults with B-acute lymphoblastic leukemia","volume":"146","author":"McNerney","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib53","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib54","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib55","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib56","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib57","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jtct.2025.01.152","article-title":"Clinical Factors Associated with Prolonged Cytopenias in Children and Young Adults Treated with CD19-Directed CAR T Cells (CAR19) for Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy","volume":"31","author":"Myers","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib58","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib59","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood-2023-189921","article-title":"Risk Factors and Outcomes for Hematotoxicity Following Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia","volume":"142","author":"McNerney","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib60","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2024.286027","article-title":"Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies","volume":"110","author":"Beyar-Katz","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201171_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.omton.2026.201171_bib62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib63","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.omton.2026.201171_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib65","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1182\/bloodadvances.2025016149","article-title":"Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR Analysis","volume":"9","author":"Rangarajan","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib66","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1182\/bloodadvances.2025016824","article-title":"Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel","volume":"9","author":"Naik","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012436","article-title":"Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL","volume":"13","author":"Culbert","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib68","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib69","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201171_bib70","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/MOP.0000000000000437","article-title":"Updates in the biology and therapy for infant acute lymphoblastic leukemia","volume":"29","author":"Guest","year":"2017","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.omton.2026.201171_bib71","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib72","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib73","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib74","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib75","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2141.2011.08846.x","article-title":"Acute lymphoblastic leukaemia in children with Down syndrome: an updated review","volume":"155","author":"Maloney","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib76","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","article-title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Laetsch","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib77","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2025-648","article-title":"CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL","volume":"146","author":"DiNofia","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib78","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib79","doi-asserted-by":"crossref","first-page":"10507","DOI":"10.1200\/JCO.2017.35.15_suppl.10507","article-title":"Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL)","volume":"35","author":"Talekar","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib80","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib81","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1182\/bloodadvances.2023010461","article-title":"CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL","volume":"7","author":"Epperly","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib82","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib83","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib84","doi-asserted-by":"crossref","first-page":"73.e1","DOI":"10.1016\/j.jtct.2021.11.019","article-title":"Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel","volume":"28","author":"Ravich","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib85","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.22.01076","article-title":"Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia","volume":"41","author":"Schultz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib86","volume":"14","author":"Molinos-Quintana","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib87","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib88","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib89","first-page":"17","article-title":"Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko","year":"2020","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.omton.2026.201171_bib90","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed\/Refractory B-Cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib91","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/bloodadvances.2025015894","article-title":"T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia","volume":"9","author":"Ma","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib92","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102268","article-title":"Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns","volume":"65","author":"Barsan","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.omton.2026.201171_bib95","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201171_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj2820","article-title":"Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL","volume":"8","author":"Bai","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201171_bib97","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib98","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib99","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","article-title":"Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients","volume":"2","author":"Biasco","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib101","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","article-title":"Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia","volume":"11","author":"An","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201171_bib102","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib103","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Dubnikov Sharon","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib105","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib106","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib107","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/bloodadvances.2025017526","article-title":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia","volume":"10","author":"Valtis","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib108","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib109","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib110","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201171_bib111","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100006","article-title":"Early ICANS recognition with a novel electroencephalogram-based deltawave detection system in patients receiving CAR T-cell therapy","volume":"1","author":"Tienstra","year":"2025","journal-title":"Blood Immunology & Cellular Therapy"},{"key":"10.1016\/j.omton.2026.201171_bib113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jha2.335","article-title":"Role of bridging therapy during chimeric antigen receptor T cell therapy","volume":"3","author":"Bhaskar","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.omton.2026.201171_bib114","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children\/Young Adults with Relapsed\/Refractory B Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib115","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3324\/haematol.2023.283780","article-title":"Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic B-lineage leukemia in children and young adults","volume":"109","author":"Feuchtinger","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201171_bib116","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib117","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib118","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","article-title":"Evolving strategies for addressing CAR T-cell toxicities","volume":"44","author":"Rankin","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.omton.2026.201171_bib120","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","article-title":"Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques","volume":"132","author":"Nellan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib121","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib122","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","article-title":"Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma","volume":"9","author":"Frigault","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib123","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood-2025-712","article-title":"Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R\/R B-cell lymphoma: An inverse probability of treatment weighting analysis","volume":"146","author":"Easwar","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib124","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1182\/blood-2023-172695","article-title":"Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis","volume":"142","author":"Liang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib125","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib126","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib127","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.2023023699","article-title":"How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL","volume":"144","author":"Muffly","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib128","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2026.201171_bib129","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2022016937","article-title":"How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL","volume":"141","author":"Myers","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib130","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib131","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1182\/bloodadvances.2024014641","article-title":"Incidence of preexisting B-cell aplasia in B-ALL: implications for post-CAR T-cell monitoring","volume":"8","author":"Sahai","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib132","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/j.jtct.2025.01.318","article-title":"Establishing Concordance of Next Generation Sequencing and Flow Cytometry Measures of B-Cell Recovery Post-CAR T Cell Therapy in B-ALL","volume":"31","author":"Hamidi","year":"2025","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/j.omton.2026.201171_bib133","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41375-019-0570-1","article-title":"Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study","volume":"34","author":"Thastrup","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70452","article-title":"Cerebrospinal Fluid Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study in China","volume":"13","author":"Tu","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2026.201171_bib135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MPH.0000000000002765","article-title":"Cerebral Spinal Fluid Parameters Following CD19-Targeted Therapies in Children and Young Adults","volume":"46","author":"Leib","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib136","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70247","article-title":"Harmonization on defining B-cell recovery post CD19-CAR T-cell therapy in B-cell acute lymphoblastic leukemia: An international consensus statement","volume":"9","author":"Lamble","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.omton.2026.201171_bib137","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820956993","article-title":"Applications of PET in Diagnosis and Prognosis of Leukemia","volume":"19","author":"Zhao","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.omton.2026.201171_bib138","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jtct.2021.10.003","article-title":"Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival Advantage","volume":"28","author":"Summers","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib139","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00277-021-04451-w","article-title":"Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis","volume":"100","author":"Hu","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.omton.2026.201171_bib140","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jtct.2021.10.011","article-title":"Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation","volume":"28","author":"Molina","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib141","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30271","article-title":"Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel","volume":"70","author":"Galletta","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib142","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","article-title":"Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004483","article-title":"Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation","volume":"10","author":"Holland","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib144","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib145","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/bloodadvances.2023011168","article-title":"Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy","volume":"8","author":"Gabelli","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib146","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ejh.14087","article-title":"Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation","volume":"112","author":"Canale","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.omton.2026.201171_bib147","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/j.clml.2024.12.014","article-title":"Effect of TKI Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation on Recurrence of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia p190 and p210 Transcripts: A Multicentre Study","volume":"25","author":"Zhen","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.omton.2026.201171_bib148","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14740\/jmc4287","article-title":"Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia","volume":"15","author":"Amin Muhammad","year":"2024","journal-title":"J. Med. Cases"},{"key":"10.1016\/j.omton.2026.201171_bib149","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/bloodadvances.2024014518","article-title":"Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy","volume":"9","author":"Friedes","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib150","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.12.002","article-title":"Mechanisms of resistance to CAR T cell therapies","volume":"65","author":"Singh","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omton.2026.201171_bib151","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib152","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201171_bib153","first-page":"183","article-title":"Humanized Chimeric Antigen Receptor (CAR) T cells","volume":"3","author":"Kozani","year":"2021","journal-title":"J. Cancer Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib154","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib155","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib156","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115973","article-title":"CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients","volume":"44","author":"Cook","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201171_bib158","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omton.2026.201171_bib159","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201171_bib160","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib161","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","article-title":"Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia","volume":"121","author":"Haso","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib162","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020303","article-title":"CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201171_bib163","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.2024024517","article-title":"How I treat postimmunotherapy relapsed B-ALL","volume":"145","author":"Lamble","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib164","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib165","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011549","article-title":"CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy","volume":"13","author":"Myers","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib166","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib167","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood-2014-11-612903","article-title":"Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein","volume":"126","author":"Qin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib168","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201171_bib169","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib170","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib171","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(23)00436-9","article-title":"Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study","volume":"24","author":"Pan","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib172","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1182\/blood-2021-148881","article-title":"SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL","volume":"138","author":"Annesley","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib173","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib174","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.1002\/ajh.27076","article-title":"Long-term follow-up of tandem CD19\/CD22 CAR T-Cells in r\/r B-ALL patients with high-risk features","volume":"98","author":"Cui","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2026.201171_bib175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib176","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/bloodadvances.2022008559","article-title":"Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function","volume":"7","author":"Leung","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib177","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012822","article-title":"Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time","volume":"13","author":"Salas-Benito","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib178","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib179","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2024-204200","article-title":"Safety and Efficacy of Bicistronic CD19\/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia","volume":"144","author":"Wan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib180","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2024-198259","article-title":"Initial Experience with CD19\/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies","volume":"144","author":"Duncan","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib181","article-title":"Allogeneic CAR Cell Therapy-More Than a Pipe Dream","volume":"11","author":"Caldwell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib182","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3324\/haematol.2023.284604","article-title":"Allogeneic chimeric antigen receptor T cells for children with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Locatelli","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201171_bib183","first-page":"146","article-title":"Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL","volume":"142","author":"Del Bufalo","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201171_bib184","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","article-title":"Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant","volume":"35","author":"Zhang","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201171_bib185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201171_bib186","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201171_bib187","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201171_bib188","article-title":"Advances in CAR-NK cell therapy for hematological malignancies","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201171_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010117","article-title":"CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer","volume":"15","author":"W\u0142odarczyk","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201171_bib190","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib191","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201171_bib192","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201171_bib193","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib194","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jadohealth.2018.10.297","article-title":"Development of a Pediatric Fertility Preservation Program: A Report From the Pediatric Initiative Network of the Oncofertility Consortium","volume":"64","author":"Moravek","year":"2019","journal-title":"J. Adolesc. Health"},{"key":"10.1016\/j.omton.2026.201171_bib195","doi-asserted-by":"crossref","first-page":"605.e1","DOI":"10.1016\/j.jtct.2022.06.002","article-title":"Fertility and CAR T-cells: Current practice and future directions","volume":"28","author":"Ligon","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.omton.2026.201171_bib196","article-title":"CONQUER Studies CAR T-cell Long-term Effects","volume":"2025","year":"2025"},{"key":"10.1016\/j.omton.2026.201171_bib197","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201171_bib198","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","article-title":"Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults","volume":"8","author":"Lamble","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib199","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","article-title":"Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy","volume":"6","author":"Hsieh","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201171_bib200","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/2643-3230.BCD-23-0272","article-title":"The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy","volume":"5","author":"Abou-El-Enein","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2026.201171_bib201","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia","volume":"36","author":"Lin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med. (Lond.)"},{"key":"10.1016\/j.omton.2026.201171_bib203","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/S1470-2045(24)00736-8","article-title":"New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis","volume":"26","author":"Pearson","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201171_bib204","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:18:45Z","timestamp":1793913525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":204,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2950329926000470"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201171","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201171"}}